—更好的抑制剂，金标准的化合物库
致电  021-50967598
或联系  在线客服QQ

BEZ235

目录号 M1671 所有产品仅供科研使用，严禁用于人或动物的治疗等任何其他用途，不为任何个人提供产品和服务  

BEZ235 (NVP-BEZ235, Dactolisib) 是一种咪唑并喹啉衍生物，能ATP竞争性的抑制PI3K和mTOR，对p110α/γ/δ/β和mTOR(p70S6K)均有抑制作用，IC50分别为4 nM/5 nM/7 nM/75 nM/6 nM，对ATR也有抑制作用，IC50为21 nM；但对Akt和PDK1抑制作用微弱。

BEZ235结构式

别名：NVP-BEZ235, Dactolisib

规格 价格 库存状态
Free Sample (0.5-1 mg)  ¥ 0 中国库存现货
10mg ¥ 330 中国库存现货
50mg ¥ 715 中国库存现货
100mg ¥ 1100 中国库存现货
200mg ¥ 1595 中国库存现货
其他规格数量报价？
质量标准及产品资料
生物活性

BEZ235 (NVP-BEZ235, Dactolisib) 是一种咪唑并喹啉衍生物，能ATP竞争性的抑制PI3K和mTOR，对p110α/γ/δ/β和mTOR(p70S6K)均有抑制作用，IC50分别为4 nM/5 nM/7 nM/75 nM/6 nM，对ATR也有抑制作用，IC50为21 nM；但对Akt和PDK1抑制作用微弱。BEZ235是ATP竞争性的PI3K和mTOR抑制剂 ，作用于p110α, p110γ, p110δ 和 p110β的IC50分别为4, 5, 7和75 nM。BEZ235 (NVP-BEZ235)也是mTORC1/2 催化剂的抑制剂。BEZ235明显降低mTOR激活激酶p70S6K的磷酸化水平。

使用AbMole产品发表的文献
产品使用成果展示
数据来源 Cancer Biol Ther (2018). Figure 3. BEZ235 (AbMole BioScience)
方法 CCK-8 assay
细胞系/动物模型 RCC 786-0 cell line
浓度 10 mmol/L
处理时间 48 or 72 h
实验结果 These IC50 values were obviously lower than that of the compounds BEZ235 and BKM120, which may be promising candidates for development as new drugs targeting the PI3K pathway.
数据来源 Apoptosis (2018). Figure 6. NVP-BEZ235 (Abmole Bioscience. USA)
方法 Western Blot
细胞系/动物模型 HT29 and SW480 cells
浓度 96 nmol/l
处理时间 24 h
实验结果 Resembling the WB results from the BZA treatment, the inhibitors AG490, NVP-BEZ23 and AZD6244 imitated BZA function, down-regulating the pivotal protein of the JAK/STAT3, PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signal pathways
数据来源 Apoptosis (2018). Figure 5. NVP-BEZ235 (Abmole Bioscience. USA)
方法 cell apoptosis assay
细胞系/动物模型 HT29 and SW480 cells
浓度 96 nmol/l
处理时间 24 h
实验结果 In addition, using the respective AG490 (50 μmol/l), NVP-BEZ235 (96 nmol/l) and AZD6244 (32 μmol/l) inhibitors for 24 h to mimic the BZA effect in colon cancer cells, we observed that the Bad/Bcl-2 ratio was significantly up-regulated and that Ki-67 mRNA expression was substantially down-regulated in this treatment group compared with the control group
数据来源 Cell Death & Disease (2018). Figure 6. BEZ235 (Abmole Bioscience)
方法 IHC analysis
细胞系/动物模型 Tumor-bearing nude mice
浓度 15 mg/kg
处理时间 4 weeks
实验结果 Following BEZ235 treatment with or without ABT263, the expression of MCL-1 was suppressed while PUMA was increased; correspondingly, the expressions of p-AKT and p-4EBP1 were significantly suppressed.
数据来源 Cell Death & Disease (2018). Figure 5. BEZ235 (Abmole Bioscience)
方法 oral gavage
细胞系/动物模型 Tumor-bearing nude mice
浓度 15 mg/kg
处理时间 4 weeks
实验结果 Our results showed that combination therapy of BEZ235 and ABT263 significantly suppressed tumor growth, comparing with each drug treatment alone.
数据来源 Cell Death & Disease (2018). Figure 4. BEZ235 (Abmole Bioscience)
方法 CO-IP analysis
细胞系/动物模型 MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells
浓度 1 μM
处理时间 24 h
实验结果 BIM and BAK were obviously released to trigger apoptosis once MCL-1 was suppressed by adding BEZ235 in the presence of ABT-263. Of note, although PUMA was upregulated by BEZ235, less PUMA was bound to MCL-1 than control group due to inhibition of MCL-1.
数据来源 Cell Death & Disease (2018). Figure 3. BEZ235 (Abmole Bioscience)
方法 Immunoblotting analysis
细胞系/动物模型 MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells
浓度 1 μM
处理时间 24 h
实验结果 We found that, besides MCL-1, the expression of PUMA but not other members was significantly increased following treatment of BEZ235 with or without ABT263 in MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells.
数据来源 Cell Death & Disease (2018). Figure 2. BEZ235 (Abmole Bioscience)
方法 colony formation assays
细胞系/动物模型 MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells
浓度 1 μM
处理时间 24 h
实验结果 The results showed that AZD8055 or BEZ235 in combination with ABT263 strongly inhibited cell proliferation in different TNBC cell lines.
数据来源 Cell Death & Disease (2018). Figure 1. BEZ235 (Abmole Bioscience)
方法 Immunoblotting analysis
细胞系/动物模型 TNBC cell lines
浓度 1 μM
处理时间 24 h
实验结果 We found the mTOR inhibitors, especially the BEZ235 and AZD8055, could significantly inhibit the phosphorylation of AKT and 4EBP1 and efficiently led to decreasing MCL-1 expression.
数据来源 Oncol Rep (2014). Figure 2. BEZ235
方法 apoptosis assay
细胞系/动物模型 OCCC cells
浓度 10 and 100 nM
处理时间 72 h
实验结果 OVISE cells were arrested at the G1 phase, but did not exhibit apoptosis (denoted by an increased proportion of cells in sub-G1), after 72 h of treatment with 10 and 100 nM NVP-BEZ235 (Fig. 2A).
数据来源 Oncol Rep (2014). Figure 1. BEZ235
方法 Western blot
细胞系/动物模型 OVISE cells
浓度 10 and 100 nM
处理时间 6 or 24 h
实验结果 Treatment with NVP-BEZ235 suppressed pAKT expression, while treatment with temsirolimus did not. Similar results were observed in the KK cells.
实验参考
体外实验*
细胞系 MKN45, BT474, SNU216 and NCI-N87 cell lines
方法 Cell viability assay Cells were seeded at a density of 2000 cells per well in a 96-well plate and incubated overnight in complete medium. Cells were treated with either trastuzumab, BEZ235, Everolimus, AZD6244 alone, or trastuzumab combined with BEZ235 or Everolimus or AZD6244. After 72 h of incubation, cell viability was determined using the MTS tetrazolium substrate (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, Madison, WI, USA) following the manufacturer’s instructions. The absorbance was measured at 490 nm using a spectrophotometer. All experiments were repeated three times with at least triplicate readings for each concentration.
浓度 0~800nM
处理时间 72h

*上述方法来自公开文献，仅供相同目的实验参考。如实验目的、材料、方法不同，请参考其他文献。

体内实验*
动物模型 Xenograft models in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice
配制 BEZ235 was formulated in 0.9 % NaCl as a homogeneous suspension (9 mg/mL) and stored at 4 °C until further use in the in vivo experiments.
剂量 45 mg/kg body weight, daily
给药处理 oral gavage

*上述方法来自公开文献，仅供相同目的实验参考。如实验目的、材料、方法不同，请参考其他文献。

化学性质
分子量 469.55
分子式 C30H23N5O
CAS号 915019-65-7
溶解性（25°C） DMSO 3 mg/mL
储存条件 粉末型式       -20°C   3年；4°C   2年
溶于溶剂       -80°C   6个月；-20°C   1个月
运输方式 冰袋运输，根据产品的不同，可能会有相应调整。
储备液配制

*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前，需考虑其在不同溶剂中的溶解度限制。

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.1297 mL 10.6485 mL 21.297 mL
5 mM 0.4259 mL 2.1297 mL 4.2594 mL
10 mM 0.213 mL 1.0648 mL 2.1297 mL
不同实验动物依据体表面积的等效剂量转换表（参考来源于公开文献）
小鼠 大鼠 兔 豚鼠 仓鼠 狗
重量 (kg) 0.02 0.15 1.8 0.4 0.08 10
体表面积 (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km 系数 3 6 12 8 5 20
动物 A (mg/kg) = 动物 B (mg/kg) ×  动物 B的Km系数
动物 A的Km系数

例如，依据体表面积折算法，将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量，需要将20 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到化合物用于大鼠的等效剂量为10 mg/kg。

参考文献

[1] Civallero et al. Expert Opin Investig Drugs. NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

[2] Karar et al. Cancer Biol Ther. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia.

[3] Roberts et al. Clin Cancer Res. Combined PI3K/mTOR and MEK Inhibition Provides Broad Anti-Tumor Activity in Faithful Murine Cancer Models.

[4] Lin et al. J Chromatogr B Analyt Technol Biomed Life Sci. Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

[5] Sally K Martin, et al. J Bone Miner Res. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells

100%好运必中
ChemBridge—化合物库中的金标准
  获取最新目录册
Abmole最新目录册
其他相关的PI3K产品
SNV4818

SNV4818是一款潜在同类最佳的（best-in-class）突变选择性PI3K-α抑制剂，对H1047X突变体具有优异选择性，同时对相关E545/542X突变体具有中等选择性。
hSMG-1 inhibitor 11j

hSMG-1 inhibitor 11j，一种嘧啶衍生物，是有效的和选择性的 hSMG-1 抑制剂，IC50 值为 0.11 nM。
RLY-2608

RLY-2608是一种首创的（first-in-class），具有口服活性的，选择性 PI3Ka 变构抑制剂。
EDI048

EDI048 (化合物1.16) 是一种口服有效的 Cryptosporidium PI4K 抑制剂，可用于隐孢子虫病的研究。
PI3Kδ-IN-13

PI3Kδ-IN-13 是一种 PI3Kδ 抑制剂 (IC50=2.6 nM)。




关键词：BEZ235, NVP-BEZ235, Dactolisib, BEZ235供应商, PI3K抑制剂, 购买BEZ235, BEZ235溶解度, BEZ235结构式








021-50967598      
2118621495      
inquiry@abmole.cn

 
AbMole
服务与支持
技术资源
联系我们



产品仅供科学研究或药证申报的用途使用，不为任何个人或者非科研性质的其他用途提供服务。

Copyright © 2010-2022 AbMole版权所有    沪ICP备16047849号   沪公网安备 31011502012228号